MNKD [NASD]
MannKind Corporation
Index- P/E- EPS (ttm)-0.38 Insider Own1.60% Shs Outstand251.89M Perf Week22.26%
Market Cap842.98M Forward P/E- EPS next Y-0.08 Insider Trans3.22% Shs Float237.04M Perf Month9.52%
Income-94.00M PEG- EPS next Q-0.09 Inst Own45.40% Short Float10.07% Perf Quarter-4.66%
Sales70.00M P/S12.04 EPS this Y-26.30% Inst Trans0.54% Short Ratio6.61 Perf Half Y-21.87%
Book/sh-0.92 P/B- EPS next Y21.40% ROA-33.60% Target Price6.00 Perf Year-13.21%
Cash/sh0.71 P/C5.19 EPS next 5Y35.60% ROE46.40% 52W Range2.49 - 5.53 Perf YTD-15.79%
Dividend- P/FCF- EPS past 5Y-17.50% ROI-37.30% 52W High-33.45% Beta1.97
Dividend %- Quick Ratio3.30 Sales past 5Y-15.50% Gross Margin39.60% 52W Low47.79% ATR0.25
Employees348 Current Ratio3.40 Sales Q/Q-31.00% Oper. Margin- RSI (14)60.39 Volatility9.51% 8.19%
OptionableYes Debt/Eq- EPS Q/Q-97.10% Profit Margin- Rel Volume1.57 Prev Close3.51
ShortableYes LT Debt/Eq- EarningsMay 05 AMC Payout- Avg Volume3.61M Price3.68
Recom1.70 SMA2018.01% SMA507.77% SMA200-9.79% Volume5,675,833 Change4.84%
May-14-21Initiated RBC Capital Mkts Sector Perform $5
Dec-24-19Initiated Oppenheimer Outperform $2.50
Oct-25-19Initiated Cantor Fitzgerald Overweight $3
May-14-19Initiated BTIG Research Buy $3
Mar-04-19Initiated SVB Leerink Outperform $3
Feb-22-19Initiated SVB Leerink Outperform $3
Feb-28-18Downgrade Maxim Group Hold → Sell $1
Nov-01-17Downgrade Maxim Group Buy → Hold
Oct-10-17Initiated H.C. Wainwright Buy $7
Oct-06-17Reiterated Maxim Group Buy $4 → $7
Aug-11-17Initiated Maxim Group Buy $4
May-10-16Reiterated RBC Capital Mkts Underperform $0.15 → $0.20
May-10-16Reiterated Piper Jaffray Underweight $0.05 → $0.10
Jan-06-16Reiterated RBC Capital Mkts Underperform $1 → $0.15
Jan-06-16Reiterated Piper Jaffray Underweight $1.50 → $0.05
Nov-04-15Downgrade RBC Capital Mkts Outperform → Underperform $9 → $1
Sep-09-15Downgrade Piper Jaffray Neutral → Underweight
Aug-03-15Reiterated RBC Capital Mkts Outperform $10 → $9
May-11-15Reiterated MLV & Co Hold $7 → $4
May-11-15Downgrade JP Morgan Neutral → Underweight
May-19-22 06:00AM  
May-17-22 06:06AM  
May-09-22 06:00AM  
May-06-22 01:30AM  
May-05-22 05:25PM  
04:00PM  
May-04-22 06:15PM  
Apr-28-22 06:00AM  
Apr-27-22 10:35AM  
06:05AM  
Apr-21-22 10:38AM  
Mar-28-22 06:05AM  
Mar-22-22 06:05AM  
Mar-08-22 06:05AM  
Mar-07-22 05:59AM  
Mar-03-22 05:25AM  
Feb-25-22 12:30AM  
Feb-24-22 04:00PM  
06:05AM  
Feb-21-22 09:05AM  
Feb-10-22 06:05AM  
Jan-24-22 05:38PM  
Jan-11-22 07:14AM  
Jan-05-22 06:10AM  
06:05AM  
Dec-06-21 06:05AM  
Nov-09-21 07:55PM  
04:05PM  
06:05AM  
Nov-05-21 07:05AM  
Nov-02-21 06:05AM  
Oct-27-21 03:03PM  
Oct-20-21 01:28AM  
Oct-19-21 10:29AM  
Oct-18-21 02:38PM  
02:37PM  
12:37PM  
11:42AM  
09:20AM  
08:45AM  
06:36AM  
06:02AM  
06:00AM  
Oct-04-21 08:11AM  
07:05AM  
07:05AM  
Sep-30-21 07:43AM  
Sep-29-21 04:24PM  
Sep-28-21 10:05AM  
06:05AM  
Sep-15-21 06:05AM  
Sep-07-21 09:54AM  
06:05AM  
06:00AM  
Aug-14-21 03:40AM  
Aug-12-21 11:30AM  
Aug-11-21 05:15PM  
04:00PM  
Aug-04-21 06:48AM  
06:48AM  
06:15AM  
Aug-03-21 09:00AM  
Jul-29-21 11:00AM  
Jul-28-21 03:03PM  
Jul-09-21 04:52AM  
Jun-29-21 09:34AM  
Jun-28-21 06:15AM  
04:15AM  
Jun-25-21 11:35AM  
Jun-17-21 09:40AM  
Jun-16-21 10:59AM  
07:26AM  
06:15AM  
06:00AM  
05:04AM  
Jun-10-21 06:15AM  
Jun-08-21 05:00PM  
Jun-03-21 06:00AM  
May-25-21 04:35AM  
May-20-21 09:00AM  
May-13-21 09:00AM  
09:00AM  
08:30AM  
May-12-21 04:00PM  
May-11-21 09:00AM  
May-05-21 09:00AM  
Apr-28-21 12:33PM  
Apr-26-21 09:00AM  
Apr-19-21 06:00AM  
Mar-16-21 09:00AM  
Mar-15-21 08:00AM  
Mar-10-21 05:00PM  
Mar-02-21 05:00PM  
06:30AM  
Mar-01-21 07:00AM  
04:47AM  
Feb-26-21 10:05AM  
01:01AM  
Feb-25-21 08:00AM  
Feb-24-21 02:57PM  
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary arterial hypertension; and Thirona Bio to evaluate the therapeutic potential of TGF- inhibitor for the treatment of pulmonary fibrosis. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MUNDKUR CHRISTINEDirectorFeb 28Buy2.7127,67574,999254,493Mar 01 05:00 PM
HOOPER ANTHONY CDirectorFeb 28Buy2.7140,000108,400338,394Mar 01 05:00 PM
Galindo AlejandroChief Commercial OfficerFeb 28Buy2.7136,90099,999576,690Mar 01 05:01 PM
Castagna MichaelChief Executive OfficerJan 31Buy3.172,3347,3991,505,628Feb 02 05:00 PM
Tross Stuart AChief People & Workpl OfficerJan 31Buy3.174,25413,485624,785Feb 02 05:00 PM
Galindo AlejandroChief Commercial OfficerJan 31Buy3.172,3347,399540,320Feb 02 05:00 PM
Binder Steven B.Chief Financial OfficerJan 31Buy3.177112,254534,178Feb 02 05:00 PM
Thomson DavidEVP Genl Counsel & SecretaryAug 27Sale4.644,10019,024567,391Aug 27 09:01 PM
Castagna MichaelChief Executive OfficerJul 30Buy2.995,00014,9501,538,652Aug 02 08:00 PM
Galindo AlejandroChief Commercial OfficerJul 30Buy2.995,00014,950547,602Aug 02 08:00 PM
Tross Stuart AChief People & Workpl OfficerJul 30Buy2.994,47613,383634,708Aug 02 08:00 PM
Binder Steven B.Chief Financial OfficerJul 30Buy2.997482,237547,644Aug 02 08:00 PM